without a drug on the market until this week. Trading in the $120 range with a market cap over $9 B., traded at less than $1.00 four or five years ago. They had the added advantage of partnering with J&J on a drug expecting a market in the billions.
The point is; upon further success in Ph2 and with a market potential of rxi-109 in the billions, many big pharmas (with dire needs to add to their pipelines) will partner to or purchase RXI IMHO. The good news is that the longer it takes outside interest, (again if we show continued success), the better. Dr. Cauwenbergh did make mention of same, and that he would wait until further advance.
Upon reviewing all the posts of yesterday, it was stated by almost all the anything can happen, and thats true of course, but I for one am not moved by RXI's daily price fluctuations, yes, I like it when the stock goes up. My main concern is the progress of rxi-109 , and some new drugs they have begun working on.
A point of interest; Both Dr. Cauwenbergh and Mr Dorman have many decades in management with J&J....Hmmmm
good luck All
I'll share a few thoughts that I just sent out to some friends outside of this board..
Hello t All, and thank you for the valuable information. You may know that I am majority invested in RXI, but still hold fair amount in GALE.
For what its worth, my currant take on RXII is mainly that all is on target in every way as planned.
Yesterday's news of Ph2 commencing gave the stock a little jolt, next month or so may be more telling after the Ph1b cohort results which will give them a better handle on dosages for the three Ph2 trials. Michael made a good point in that the trials are timely due to the relatively quick skin healing and the added plus of being visible. Just note how quickly Ph1 concluded.
An unfortunate set back that we are not on nasdaq as yet, and hence at the mercy to a degree of the MM's unsavory behavior,IMHO.
The fact that They have $15M or so on hand, and with a burn rate of $2M per Q a big plus, not excluding the fact that possible or perhaps probable future dilution will occur.
Ph1 showed the effectiveness in scar reduction up to 43% per the CEO. How objective or subjective is that opinion? Good question I think, But if this is so then rxi-109 has shown to be effective then it would seem Ph2 trials are an extremely strong positive. This is the $54M question for me.
Lastly, I am impressed with Dr. Cauwenbergh, his staff, and his recent appointees of Curtis Lockshin and Paul Dorman. Add to that They continue to progress "on time and on cash" per CEO. I feel assured that in the event RXI does not succeed, it will not be due to poor management. good luck All
It has been stated by IR of RXI that a certain financing arrangement from early this year was the reason for not getting uplisted, and that it is now pending. RXI will be listed on nasdaq upon its shares trading at minimum of $4.00...............good luck All
A few more corners to turn, but keep in mind that we are in the hands of a Pro in Dr. Cauwenbergh. Management is everything in this business IMHO.
Good luck All.........
one might think it's a buy here, stictly based upon the science they possess, but on the other hand we are left with no indications as to the direction of the company.
That's the gamble now. If there were something in the works we would have heard by now IMO.
So, now we wait, buy when there is a sign to buy.....................good luck All
Many thanks grab, much appreciated, Hope all's well......................................
Appears nobody is buying your story 8889. GALE up after hours, 14M traded.
stockwatcher is right, you are and example of an idiot....................good luck All
thanks...............................good luck all
hanna, IMO you are correct. the trials for rx-109 are very short due to the nature of skin healing and complete visibility. Much different from internal testing.
One only has to see how timely Ph1 trials completed.
Good luck All
Always that possibility, BTW I have been a shareholder in GALE for about three years. Looking stonger now. Their CEO makes nearly three times RXI's CEO just for your information.
Just what do feel is the bs here? you never did anything but cry cobra.
I don't think you ever had an original thought in your head, no offense.
Good luck All
Buy more stock in a company you call"poorly managed".
Management is it. it makes or breaks a company. Afraid IMHO it was mgmt that did this one in..............good luck All
European Portfolio | North American Portfolio | Become a Member
4-traders.com, stock quotes, stock exchange, market price, stock market advice, technical analysis, stock chart analysis, Company News
Top & Flop
4-Traders Homepage Shares OTC Bulletin Board RXi Pharmaceuticals Corp US74979C1053
RXI PHARMACEUTICALS CORP
No quotes available
-- USD --.--%
1d ago RXI PHARMACEUTICALS CORP : RXi Pharmaceuticals’ Valuation Moves From Produc..
11/01 RXI PHARMACEUTICALS CORP : New Small Cap Reports on RXII, APPA and TRTC
10/16 RXI PHARMACEUTICALS CORP : 3 Reasons To Consider Investing In RXi Pharmaceu..
Summary News Company
RXi Pharmaceuticals Corp : RXi Pharmaceuticals’ Valuation Moves From Product To Platform
11/12/2013 | 10:20am US/Eastern
The RNAi space has been experiencing a robust recovery from its early failures as recent clinical trials have demonstrated its viability. For instance, Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) shares have soared more than 195% since January after the company reported favorable data for its ALN-TTRsc. This data led investors to value the stock based on its platform potential rather than its single-indication potential.
In this article, we will take a look at RXi Pharmaceuticals Inc. (OTCQX: RXII) and how its RXI-109 clinical trial could lead investors to do the same for its stock.
RXI-109 Provides Proof of Concept
RXi Pharmaceuticals? first clinical candidate, RXI-109, is a self-delivering RNAi compound being developed to reduce dermal scarring following planned surgeries. Leveraging RNAi?s ability to ?shut off? the expression of certain genes, RXI-109 works by reducing the expression of Connective Tissue Growth Factor (?CTGF?), an extracellular protein that play a key role in tissue regeneration. Elevated levels of CTGF-dependent signaling can prolong the tissue repair process and lead to pathological scarring and fibrosis There is also strong evidence that silencing CTGF locally significantly reduces scar formation.
In two Phase I clinical trials, RXI-109 did not cause any significant side-effects or toxicities, and significantly reduced the expression of CTGF in a dose-dependent manner. These effects were also observed 84 days after a single dose in its Phase Ia clinical trial, suggesting a potent and long-lasting effect on the key biomarker for abnormal scarring. With a 43% knockdown rate, the treatment silences CTGF enough to reduce scarring without inhibiting wound healing.
President and CEO, Dr. Geert Cauwenbergh commented on the results, saying, "The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI 109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids."
RXI-109 has the blockbuster potential to become a first-in-class treatment for the reduction of dermal scarring. With over 35 million surgical procedures in the U.S. each year and an aging population, there is a large and growing market for treatments to reduce dermal scarring.
Valuing the sd-rxRNA Deliver Platform
RXi Pharmaceuticals' RXI-109 is the first treatment developed using its proprietary sd-rxRNA delivery platform. By building drug-like properties into the RNAi compound, the approach enables spontaneous cellular uptake without the need for a delivery vehicle.
The company's scientists have shown in vitro and in vivo that sd-rxRNA's built-in drug-like properties enable systemic delivery in any tissue that's reachable. Using hybrid oligonucleotide compounds, the platform combines the best aspects of traditional RNAi and single-stranded antisense RNA approaches to provide high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake.
These properties suggest that the delivery platform could become the basis for a pipeline of clinical programs spanning a wide range of diseases and conditions. In fact, the platform is already being leveraged in the company's ophthalmology franchise that it acquired from OPKO Health Inc. (NYSE: OPK) that is targeting vascular endothelial growth factor ("VEGF"). Other clinical targets include liver fibrosis ("RXI-209") and CNS diseases like ALS.
The sd-rxRNA platform is protected by a wide body of intellectual property, including 11 patent families covering rxRNA compounds and technologies. With the acquisition of OPKO's assets in March of 2013, the company added rights to 97 patents and 62 patent applications, primarily in the ophthalmology space. These patents both protect the firm's existing technologies and set the stage for future potential licensing opportunities as RNAi becomes more established.
Potential Investment Opportunity
RXi Pharmaceuticals' real potential lies in licensing opportunities stemming from its potential clinical pipeline built atop the sd-rxRNA platform. With RXI-109 Phase II clinical trials starting soon, the company will have the opportunity to prove that it's sd-rxRNA platform works as-advertised. Success in these trials could transform the company from a single-product to a platform play by opening up its licensing potential in numerous other markets.
Hope we have a good week. This tiny company is able to accomplish what those with ten times the staff are unable to "on time and on cash" per the CEO.
As they expand on their pipeline we could see some amazing things. I witnessed same with ALNY of which I took a small position at $8 or so. See bio's post of yesterday.
Also we await (this month) results of additional Ph1b cohort study. Looking good I think.
Good luck All
News out this morning. site would not let me paste article here........good luck All